Actual patients discuss their treatment journey and why they started on SCEMBLIX
For US residents only.
Be Open to a Different Approach
Al was diagnosed with Ph+ CML in chronic phase in 1997, before the first tyrosine kinase inhibitor (TKI) was available to treat the disease. He provides insights about being open to discussing the use of different medications with your doctor if you are not meeting your treatment goals or if side effects are becoming intolerable.
Please note, Al cannot provide clinical advice or counseling. For medical questions, speak with your doctor.
Al is an actual patient who has been compensated by Novartis Pharmaceuticals Corporation for participating in the SCEMBLIX Peers program.
Would you say CML is a “good cancer?”
What results have you seen with SCEMBLIX?
What is SCEMBLIX and what are the possible side effects?
How did you feel when you realized the second or third TKI was not working?
If a second or third TKI isn’t working, why might someone hesitate to switch?
Why have you had to switch TKIs more than some people?
How important is the patient-doctor relationship?
What can someone do if they're not seeing results with their current TKI?
Have you ever thought twice about discussing side effects with your doctor?
How do you discuss side effects with your doctor?
Have you set any treatment goals with your doctor?
Why were you open to trying a different TKI?
Do you have any concerns when you go for blood tests?
Where can CML patients and caregivers find support?
What financial support options are available for eligible SCEMBLIX patients?
Can patients starting on SCEMBLIX receive one-on-one support?
Learn how to take the first step in sharing your story with other patients with CML